Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • BTC—
…Loading prices
HIMS

NAD rules on Kenvue complaint, some HIMS hair-regrowth ad claims must be modified or dropped

Sources (4)

A new first-hand business development: the advertising self-regulator NAD (the National Advertising Division of BBB National Programs) has ruled on a complaint by Kenvue (parent company of Rogaine, the minoxidil brand) about advertising claims for HIMS's compounded topical hair-regrowth products (official GlobeNewswire announcement, 24 Aug).

Read more

The outcome is mixed. The combination-efficacy claim was supported. But the 'doctor-trusted ingredients' claim must be modified, with details of a survey of 250 dermatologists disclosed; the 'dermatologist-recommended' claim must be dropped; and the safety and side-effect claims were also recommended for change. After the FTC lawsuit of 29 Jul and Visa's acquirer monitoring of 22 Aug, this is the third independent outside party to point, each from its own angle, at the same underlying problem: HIMS's aggressive marketing, billing and claims practices. The front has widened from GLP-1s and privacy to claims in the core hair-regrowth business. The direct financial impact is small (no fine, low remediation cost), but the symbolic significance and the compliance cost point the same way, and fierce competition is turning industry self-regulation into a weapon.

Key evidence

  • Official GlobeNewswire announcement, 24 Aug: NAD has ruled on Kenvue's complaint about HIMS advertising for compounded topical hair-regrowth products.
  • Win: the combination-efficacy claim (finasteride plus minoxidil works better than either alone) had a reasonable basis and was supported.
  • Loss 1: the general claim of 'doctor-trusted ingredients' must be modified, and the specific results of the survey of 250 independent dermatologists must be clearly disclosed (by ingredient, combination and population).
  • Loss 2: the 'dermatologist-recommended' claim must be discontinued, as NAD found the survey insufficient to support it.
  • Loss 3: the safety and side-effect claims were likewise recommended to be modified or discontinued.
  • The complainant, Kenvue, is the consumer health spin-off from Johnson & Johnson and the parent company of Rogaine (minoxidil). It has the money and the motive to keep fighting.
Show 3 more
  • Products involved: Hims finasteride and minoxidil spray and serum, and the Hers hair-regrowth range for post-menopausal women.
  • A third independent outside party points to the same underlying problem: the FTC (lawsuit of 29 Jul, with deceptive advertising one of the 3 main allegations), Visa acquirer monitoring (22 Aug) and NAD (today).
  • NAD's ruling is not binding, but if a company refuses to comply the usual course is a referral to the FTC. With the FTC already suing HIMS, HIMS will most likely comply.

Catalysts to watch

  • HIMS's formal response to the NAD ruling (accept, appeal or refuse to comply)
  • If HIMS refuses to comply, NAD's follow-up referral to the FTC
  • The Q4 profit jump, the next proof point on the core dispute (revenue up 38% YoY against deteriorating earnings quality)
  • Watching hair-regrowth customer conversion once high-converting trust endorsements such as 'doctor-trusted' and 'dermatologist-recommended' are removed
  • Further complaints from Kenvue or other competitors that keep using the advertising self-regulation process to apply compliance pressure

Risks

  • On its own this is not a fundamental turning point: the fine is zero and remediation costs are very low (rewriting copy, adding disclosures).
  • But the main thread, independent outside parties pointing at HIMS's marketing and compliance practices, continues, and it is corroborated by 3 independent parties: the FTC lawsuit, Visa monitoring and NAD.
  • Marketing language is restricted: 'doctor-trusted' and 'dermatologist-recommended' are high-converting trust endorsements, and dropping them may modestly weigh on hair-regrowth customer conversion.
  • The front has widened from GLP-1s and privacy to claims in the core hair-regrowth business, hitting the long-established vertical where HIMS started and which has its steadiest cash flow.
  • Fierce competition is turning regulation and self-regulatory processes into tools (Kenvue is using NAD to apply compliance pressure).
Show 2 more
  • The core dispute is unchanged (+38% YoY against deteriorating earnings quality and rising legal and compliance cost exposure), and the risk/reward leans cautious.
  • Today's sharp intraday fall in the share price was the market reaction to Visa acquirer monitoring and FTC sentiment (content already covered).

Sources 4

  1. GlobeNewswire official announcement, 24 Aug (NAD ruling)
  2. BBB National Programs / National Advertising Division
  3. FTC lawsuit against HIMS, 29 Jul (deceptive advertising is one of the 3 main allegations)
  4. Visa acquirer monitoring, already published on 22 Aug

A brief is a lead for our research, not a verified conclusion or advice.